The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
New Multiple Sclerosis Phenotypic Classification
Abstract
Background: In 1996, the clinical course of multiple sclerosis (MS) was characterized as relapsing-remitting, primary progressive, secondary progressive or progressive relapsing. Since then, an increased understanding of MS and its pathology prompted a re-examination of these clinical phenotypes. Main recommendations of the 2013 revisions are provided herein. Summary: Clinically isolated syndrome has been added, and progressive relapsing MS has been eliminated, from the clinical course descriptions. All forms of MS should be further subcategorized as either active or non-active. Active MS is defined as the occurrence of clinical relapse or the presence of new T2 or gadolinium-enhancing lesions over a specified period of time, preferably at least one year. An additional subcategory for patients with progressive MS differentiates between those who have shown signs of disability progression over a given time period and those who have remained stable. The term ‘worsening' is recommended to describe patients whose disease is advancing for any reason, whereas ‘disease progression' should be reserved for those with progressive disease who are truly progressing (as opposed to worsening from a relapse). The term ‘benign' should be used with caution as the course of MS can worsen at any time, even after many years of apparent stability. Key Messages: Newer characterizations of MS phenotypes include a consideration of disease activity (based on the clinical relapse rate and imaging findings) and disease progression. Accurate clinical course descriptions are useful for communication, prognostication, clinical trial design and to guide everyday clinical decision-making. © 2014 S. Karger AG, Basel
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Self-citationDefining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Self-citationHawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21867 · Cited by 934
Wolinsky, J. S., Narayana, P. A., O'Connor, P., Coyle, P. K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21079 · Cited by 429
Cited by
Items 101–200 of 204
Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
Spadaro, M., Gerdes, L. A., Krumbholz, M., Ertl-Wagner, B., Thaler, F. S., Schuh, E., Metz, I., Blaschek, A., Dick, A., Brück, W., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000257 · Cited by 206
Bruton tyrosine kinase inhibitors for multiple sclerosis
Krämer, J., Bar-Or, A., Turner, T. J., & Wiendl, H. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00800-7 · Cited by 206
Reich, D. S., Arnold, D. L., Vermersch, P., Bar-Or, A., Fox, R. J., Matta, A., Turner, T., Wallström, E., Zhang, X., Mareš, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00237-4 · Cited by 204
Clinical presentation and diagnosis of multiple sclerosis
Ford, H. (2020) · Clinical Medicine · doi:10.7861/clinmed.2020-0292 · Cited by 199
Mindfulness based interventions in multiple sclerosis–a systematic review
Simpson, R., Booth, J., Lawrence, M., Byrne, S., Mair, F., & Mercer, S. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-15 · Cited by 195
Inflammation-related plasma and CSF biomarkers for multiple sclerosis
Huang, J., Khademi, M., Fugger, L., Lindhe, Ö., Novakova, L., Axelsson, M., Malmeström, C., Constantinescu, C., Lycke, J., Piehl, F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912839117 · Cited by 194
Ribbons, K. A., McElduff, P., Boz, C., Trojano, M., Izquierdo, G., Duquette, P., Girard, M., Grand’Maison, F., Hupperts, R., Grammond, P., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122686 · Cited by 190
Five Decades of Cuprizone, an Updated Model to Replicate Demyelinating Diseases
Vega-Riquer, J. M., Mendez-Victoriano, G., Morales-Luckie, R. A., & Gonzalez-Perez, O. (2019) · Current Neuropharmacology · doi:10.2174/1570159x15666170717120343 · Cited by 188
Granberg, T., Fan, Q., Treaba, C. A., Ouellette, R., Herranz, E., Mangeat, G., Louapre, C., Cohen-Adad, J., Klawiter, E. C., Sloane, J. A., et al. (2017) · Brain · doi:10.1093/brain/awx247 · Cited by 184
Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study
Manouchehrinia, A., Tench, C. R., Maxted, J., Bibani, R. H., Britton, J., & Constantinescu, C. S. (2013) · Brain · doi:10.1093/brain/awt139 · Cited by 184
Dong, Y., D’Mello, C., Pinsky, W., Lozinski, B. M., Kaushik, D. K., Ghorbani, S., Moezzi, D., Brown, D., Melo, F. C., Zandee, S., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00801-z · Cited by 181
Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis
Correale, J., Marrodan, M., & Ysrraelit, M. C. (2019) · Biomedicines · doi:10.3390/biomedicines7010014 · Cited by 167
Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome
Kantarci, O. H., Lebrun, C., Siva, A., Keegan, M. B., Azevedo, C. J., Inglese, M., Tintoré, M., Newton, B. D., Durand‐Dubief, F., Amato, M. P., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24564 · Cited by 167
Translational value of choroid plexus imaging for tracking neuroinflammation in mice and humans
Fleischer, V., Gonzalez-Escamilla, G., Ciolac, D., Albrecht, P., Küry, P., Gruchot, J., Dietrich, M., Hecker, C., Müntefering, T., Bock, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025000118 · Cited by 152
Endothelial Wnt/β-catenin signaling reduces immune cell infiltration in multiple sclerosis
Lengfeld, J. E., Lutz, S. E., Smith, J. R., Diaconu, C., Scott, C., Kofman, S. B., Choi, C., Walsh, C. M., Raine, C. S., Agalliu, I., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609905114 · Cited by 152
Assessment and impact of cognitive impairment in multiple sclerosis: An overview
Macías Islas, M. Á., & Ciampi, E. (2019) · Biomedicines · doi:10.3390/biomedicines7010022 · Cited by 144
The radiologically isolated syndrome: revised diagnostic criteria
Lebrun-Frénay, C., Okuda, D. T., Siva, A., Landes-Chateau, C., Azevedo, C. J., Mondot, L., Carra-Dallière, C., Zephir, H., Louapre, C., Durand-Dubief, F., et al. (2023) · Brain · doi:10.1093/brain/awad073 · Cited by 132
Hart, S., Fonareva, I., Merluzzi, N., & Mohr, D. C. (2005) · Quality of Life Research · doi:10.1007/s11136-004-1364-z · Cited by 128
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations
Pfeffer, G., Burke, A., Yu-Wai-Man, P., Compston, D. A. S., & Chinnery, P. F. (2013) · Neurology · doi:10.1212/01.wnl.0000437308.22603.43 · Cited by 122
Sejbaek, T., Nielsen, H. H., Penner, N., Plavina, T., Mendoza, J. P., Martin, N. A., Elkjaer, M. L., Ravnborg, M. H., & Illes, Z. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321321 · Cited by 108
Body fluid biomarkers for multiple sclerosis—the long road to clinical application
Teunissen, C. E., Malekzadeh, A., Leurs, C., Bridel, C., & Killestein, J. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.173 · Cited by 106
Albumin and multiple sclerosis
LeVine, S. M. (2016) · BMC Neurology · doi:10.1186/s12883-016-0564-9 · Cited by 105
Powell, D. J. H., Liossi, C., Schlotz, W., & Moss-Morris, R. (2017) · Journal of Behavioral Medicine · doi:10.1007/s10865-017-9840-4 · Cited by 99
Cramer, S. P., Modvig, S., Simonsen, H. J., Frederiksen, J. L., & Larsson, H. B. W. (2015) · Brain · doi:10.1093/brain/awv203 · Cited by 94
Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients
Eggers, E. L., Michel, B. A., Wu, H., Wang, S.-Z., Bevan, C. J., Abounasr, A., Pierson, N. S., Bischof, A., Kazer, M., Leitner, E., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92724 · Cited by 93
Hanken, K., Eling, P., & Hildebrandt, H. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00264 · Cited by 92
The tension between early diagnosis and misdiagnosis of multiple sclerosis
Solomon, A. J., & Corboy, J. R. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.106 · Cited by 89
Vidal-Jordana, A., Rovira, A., Calderon, W., Arrambide, G., Castilló, J., Moncho, D., Rahnama, K., Collorone, S., Toosy, A. T., Ciccarelli, O., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000207805 · Cited by 88
Earlier and more frequent diagnosis of multiple sclerosis using the McDonald criteria: Figure 1
Brownlee, W. J., Swanton, J. K., Altmann, D. R., Ciccarelli, O., & Miller, D. H. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308675 · Cited by 84
Meditation as an adjunct to the management of multiple sclerosis.
Levin, A. B., Hadgkiss, E. J., Weiland, T. J., & Jelinek, G. A. (2014) · Neurology Research International · doi:10.1155/2014/704691 · Cited by 77
Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion
Keegan, B. M., Kaufmann, T. J., Weinshenker, B. G., Kantarci, O. H., Schmalstieg, W. F., Paz Soldan, M. M., & Flanagan, E. P. (2016) · Neurology · doi:10.1212/wnl.0000000000003235 · Cited by 80
An overall view of the most common experimental models for multiple sclerosis
Dedoni, S., Scherma, M., Camoglio, C., Siddi, C., Dazzi, L., Puliga, R., Frau, J., Cocco, E., & Fadda, P. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106230 · Cited by 79
Cholinesterase inhibitors for rarer dementias associated with neurological conditions
Li, Y., Hai, S., Zhou, Y., & Dong, B. R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009444.pub3 · Cited by 78
A systematic review of modifiable risk factors in the progression of multiple sclerosis
Hempel, S., Graham, G. D., Fu, N., Estrada, E., Chen, A. Y., Miake-Lye, I., Miles, J. N. V., Shanman, R., Shekelle, P. G., Beroes, J. M., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517690270 · Cited by 77
Alschuler, K. N., & Beier, M. L. (2015) · International Journal of MS Care · doi:10.7224/1537-2073.2014-044 · Cited by 76
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
Filippini, G., Minozzi, S., Borrelli, F., Cinquini, M., & Dwan, K. (2022) · Cochrane Database Systematic Reviews · doi:10.1002/14651858.cd013444.pub2 · Cited by 75
Kallaur, A. P., Oliveira, S. R., Simão, A. N. C., Alfieri, D. F., Flauzino, T., Lopes, J., de Carvalho Jennings Pereira, W. L., de Meleck Proença, C., Borelli, S. D., Kaimen-Maciel, D. R., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9846-x · Cited by 75
Disanto, G., Benkert, P., Lorscheider, J., Mueller, S., Vehoff, J., Zecca, C., Ramseier, S., Achtnichts, L., Findling, O., Nedeltchev, K., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152347 · Cited by 76
Vermersch, P., Brieva-Ruiz, L., Fox, R. J., Paul, F., Ramio-Torrenta, L., Schwab, M., Moussy, A., Mansfield, C., Hermine, O., Maciejowski, M., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001148 · Cited by 74
Fleming, J., Hernandez, G., Hartman, L., Maksimovic, J., Nace, S., Lawler, B., Risa, T., Cook, T., Agni, R., Reichelderfer, M., et al. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458517736377 · Cited by 74
Diagnosis and Management of Progressive Multiple Sclerosis
Macaron, G., & Ontaneda, D. (2019) · Biomedicines · doi:10.3390/biomedicines7030056 · Cited by 70
“Better explanations” in multiple sclerosis diagnostic workup: A 3-year longitudinal study
Calabrese, M., Gasperini, C., Tortorella, C., Schiavi, G., Frisullo, G., Ragonese, P., Fantozzi, R., Prosperini, L., Annovazzi, P., Cordioli, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007573 · Cited by 70
Regev, K., Healy, B. C., Khalid, F., Paul, A., Chu, R., Tauhid, S., Tummala, S., Diaz-Cruz, C., Raheja, R., Mazzola, M. A., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.5197 · Cited by 68
Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis
Leocani, L., Nuara, A., Houdayer, E., Schiavetti, I., Del Carro, U., Amadio, S., Straffi, L., Rossi, P., Martinelli, V., Vila, C., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7878-1 · Cited by 66
Ostmeyer, J., Christley, S., Rounds, W. H., Toby, I., Greenberg, B. M., Monson, N. L., & Cowell, L. G. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1814-6 · Cited by 63
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD
Yan, Y., Li, Y., Fu, Y., Yang, L., Su, L., Shi, K., Li, M., Liu, Q., Borazanci, A., Liu, Y., et al. (2016) · Science China Life Sciences · doi:10.1007/s11427-015-4997-y · Cited by 63
Breastfeeding, ovulatory years, and risk of multiple sclerosis
Langer-Gould, A., Smith, J. B., Hellwig, K., Gonzales, E., Haraszti, S., Koebnick, C., & Xiang, A. (2017) · Neurology · doi:10.1212/wnl.0000000000004207 · Cited by 60
Klistorner, A., Vootakuru, N., Wang, C., Yiannikas, C., Graham, S. L., Parratt, J., Garrick, R., Levin, N., Masters, L., Lagopoulos, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122114 · Cited by 59
Bsteh, G., Hegen, H., Altmann, P., Auer, M., Berek, K., Di Pauli, F., Kornek, B., Krajnc, N., Leutmezer, F., Macher, S., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207507 · Cited by 59
Disruption of neurite morphology parallels MS progression
Spanò, B., Giulietti, G., Pisani, V., Morreale, M., Tuzzi, E., Nocentini, U., Francia, A., Caltagirone, C., Bozzali, M., & Cercignani, M. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000502 · Cited by 58
Theranostic implications of nanotechnology in multiple sclerosis: a future perspective.
Singh, A. V., Khare, M., Gade, W. N., & Zamboni, P. (2012) · Autoimmune Diseases · doi:10.1155/2012/160830 · Cited by 58
Crescentini, C., Matiz, A., Cimenti, M., Pascoli, E., Eleopra, R., & Fabbro, F. (2018) · International Journal of MS Care · doi:10.7224/1537-2073.2016-093 · Cited by 56
Snow, N. J., Wadden, K. P., Chaves, A. R., & Ploughman, M. (2019) · Neural Plasticity · doi:10.1155/2019/6430596 · Cited by 56
Plasma Biomarkers Discriminate Clinical Forms of Multiple Sclerosis
Tejera-Alhambra, M., Casrouge, A., de Andrés, C., Seyfferth, A., Ramos-Medina, R., Alonso, B., Vega, J., Fernández-Paredes, L., Albert, M. L., & Sánchez-Ramón, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128952 · Cited by 55
Fournier, A. P., Quenault, A., Martinez de Lizarrondo, S., Gauberti, M., Defer, G., Vivien, D., Docagne, F., & Macrez, R. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619424114 · Cited by 54
“The most frequent form (relapsing–remitting subtype) is characterized by unpredictable relapses followed by periods of months to years during which signs of disease activity are absent (2).”
BackgroundHuss, A. M., Halbgebauer, S., Öckl, P., Trebst, C., Spreer, A., Borisow, N., Harrer, A., Brecht, I., Balint, B., Stich, O., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8302-1 · Cited by 54
Giovannetti, A. M., Quintas, R., Tramacere, I., Giordano, A., Confalonieri, P., Messmer Uccelli, M., Solari, A., & Pakenham, K. I. (2020) · PLOS ONE · doi:10.1371/journal.pone.0231380 · Cited by 53
Environmental control of autoimmune inflammation in the central nervous system
Rothhammer, V., & Quintana, F. J. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.09.002 · Cited by 52
Gabelic, T., Ramasamy, D. P., Weinstock-Guttman, B., Hagemeier, J., Kennedy, C., Melia, R., Hojnacki, D., Ramanathan, M., & Zivadinov, R. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3653 · Cited by 51
Nuzziello, N., Vilardo, L., Pelucchi, P., Consiglio, A., Liuni, S., Trojano, M., & Liguori, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113652 · Cited by 46
Should the symptomatic region be included in dissemination in space in MRI criteria for MS?
Brownlee, W. J., Swanton, J. K., Miszkiel, K. A., Miller, D. H., & Ciccarelli, O. (2016) · Neurology · doi:10.1212/wnl.0000000000002975 · Cited by 50
Carletto, S., Tesio, V., Borghi, M., Francone, D., Scavelli, F., Bertino, G., Malucchi, S., Bertolotto, A., Oliva, F., Torta, R., et al. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2017.02083 · Cited by 49
Grech, L. B., Kiropoulos, L. A., Kirby, K. M., Butler, E., Paine, M., & Hester, R. (2018) · International Journal of MS Care · doi:10.7224/1537-2073.2016-008 · Cited by 49
Ferroptosis induces detrimental effects in chronic EAE and its implications for progressive MS
Jhelum, P., Zandee, S., Ryan, F., Zarruk, J. G., Michalke, B., Venkataramani, V., Curran, L., Klement, W., Prat, A., & David, S. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01617-7 · Cited by 49
The increasing role of Kappa free light chains in the diagnosis of multiple sclerosis
Konen, F. F., Schwenkenbecher, P., Jendretzky, K. F., Gingele, S., Sühs, K.-W., Tumani, H., Süße, M., & Skripuletz, T. (2021) · Cells · doi:10.3390/cells10113056 · Cited by 47
Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory
Rosato, R., Testa, S., Bertolotto, A., Confalonieri, P., Patti, F., Lugaresi, A., Grasso, M. G., Toscano, A., Giordano, A., & Solari, A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153466 · Cited by 46
Geladaris, A., Torke, S., & Weber, M. S. (2022) · CNS Drugs · doi:10.1007/s40263-022-00951-z · Cited by 45
Is It worth Considering Circulating microRNAs in Multiple Sclerosis?
Jagot, F., & Davoust, N. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00129 · Cited by 45
Immune-mediated processes in neurodegeneration: where do we stand?
Fakhoury, M. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8052-0 · Cited by 43
Lipoprotein markers associated with disability from multiple sclerosis
Gafson, A. R., Thorne, T., McKechnie, C. I. J., Jimenez, B., Nicholas, R., & Matthews, P. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-35232-7 · Cited by 40
Patient iPSC models reveal glia-intrinsic phenotypes in multiple sclerosis
Clayton, B. L. L., Barbar, L., Sapar, M., Kalpana, K., Rao, C., Migliori, B., Rusielewicz, T., Paull, D., Brenner, K., Moroziewicz, D., et al. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.08.002 · Cited by 38
Lesion topographies in multiple sclerosis diagnosis: A reappraisal
Arrambide, G., Tintore, M., Auger, C., Río, J., Castilló, J., Vidal-Jordana, A., Galán, I., Nos, C., Comabella, M., Mitjana, R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004715 · Cited by 38
Brola, W., Sobolewski, P., Fudala, M., Flaga, S., Jantarski, K., Ryglewicz, D., & Potemkowski, A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s109520 · Cited by 35
Post‐mortem multiple sclerosis lesion pathology is influenced by single nucleotide polymorphisms
Fransen, N. L., Crusius, J. B. A., Smolders, J., Mizee, M. R., van Eden, C. G., Luchetti, S., Remmerswaal, E. B. M., Hamann, J., Mason, M. R. J., & Huitinga, I. (2020) · Brain Pathology · doi:10.1111/bpa.12760 · Cited by 37
Relapsing and progressive MS: the sex-specific perspective
Rommer, P. S., Ellenberger, D., Hellwig, K., Haas, J., Pöhlau, D., Stahmann, A., Zettl, U. K., & on behalf of the Scientific Advisory Group of the German MS-Register by the German MS Society (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420956495 · Cited by 37
Abrevaya, S., Fittipaldi, S., García, A. M., Dottori, M., Santamaria-Garcia, H., Birba, A., Yoris, A., Hildebrandt, M. K., Salamone, P., De la Fuente, A., et al. (2020) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000868 · Cited by 34
Lazzarotto, A., Hamzaoui, M., Tonietto, M., Dubessy, A.-L., Khalil, M., Pirpamer, L., Ropele, S., Enzinger, C., Battaglini, M., Stromillo, M. L., et al. (2024) · Brain · doi:10.1093/brain/awae024 · Cited by 33
Single-cell and spatial RNA sequencing identify perturbators of microglial functions with aging
Dong, Y., Jain, R. W., Lozinski, B. M., D’Mello, C., Visser, F., Ghorbani, S., Zandee, S., Brown, D. I., Prat, A., Xue, M., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00205-z · Cited by 32
Socioeconomic disparity is associated with faster retinal neurodegeneration in multiple sclerosis
Vasileiou, E. S., Filippatou, A. G., Pimentel Maldonado, D., Kalaitzidis, G., Ehrhardt, H., Lambe, J., Saidha, S., Sotirchos, E. S., Mowry, E. M., Calabresi, P. A., et al. (2021) · Brain · doi:10.1093/brain/awab342 · Cited by 32
Hofer, L. S., Ramberger, M., Gredler, V., Pescoller, A. S., Rostásy, K., Sospedra, M., Hegen, H., Berger, T., Lutterotti, A., & Reindl, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01188 · Cited by 30
McGuire, K. B., Stojanovic-Radic, J., Strober, L., Chiaravalloti, N. D., & DeLuca, J. (2015) · International Journal of MS Care · doi:10.7224/1537-2073.2013-045 · Cited by 30
Urinary Excretion of Aluminium and Silicon in Secondary Progressive Multiple Sclerosis
Jones, K., Linhart, C., Hawkins, C., & Exley, C. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.10.028 · Cited by 30
DiSano, K. D., Royce, D. B., Gilli, F., & Pachner, A. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01821 · Cited by 30
Association Between Pain and Mindfulness in Multiple Sclerosis
Senders, A., Borgatti, A., Hanes, D., & Shinto, L. (2018) · International Journal of MS Care · doi:10.7224/1537-2073.2016-076 · Cited by 28
Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis
Rolf, L., Damoiseaux, J., Huitinga, I., Kimenai, D., van den Ouweland, J., Hupperts, R., & Smolders, J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00263 · Cited by 28
Alroughani, R., Al Hashel, J., Lamdhade, S., & Ahmed, S. F. (2012) · ISRN Neurology · doi:10.5402/2012/792192 · Cited by 28
Carletto, S., Borghi, M., Francone, D., Scavelli, F., Bertino, G., Cavallo, M., Malucchi, S., Bertolotto, A., Oliva, F., & Ostacoli, L. (2016) · BMC Neurology · doi:10.1186/s12883-016-0528-0 · Cited by 27
Online psychological interventions to improve symptoms in multiple sclerosis: A systematic review
Montañés‐Masias, B., Bort‐Roig, J., Pascual, J. C., Soler, J., & Briones‐Buixassa, L. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13709 · Cited by 27
Melanocortins, Melanocortin Receptors and Multiple Sclerosis
Lisak, R., & Benjamins, J. (2017) · Brain Sciences · doi:10.3390/brainsci7080104 · Cited by 27
Balcer, L. J., Balk, L. J., Brandt, A. U., Calabresi, P. A., Martinez-Lapiscina, E. H., Nolan, R. C., Paul, F., Petzold, A., Saidha, S., & on behalf of the IMSVISUAL Consortium (2018) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000732 · Cited by 25
Groen, K., Maltby, V. E., Lea, R. A., Sanders, K. A., Fink, J. L., Scott, R. J., Tajouri, L., & Lechner-Scott, J. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0365-7 · Cited by 21
Lowe, R., Barlow, C., Lloyd, B., Latchem-Hastings, J., Poile, V., Scoble, C., Dean-Young, A., Button, K., Playle, R., & Busse, M. (2021) · Trials · doi:10.1186/s13063-021-05245-1 · Cited by 19
MiR-124 and MiR-155 as Therapeutic Targets in Microglia-Mediated Inflammation in Multiple Sclerosis
Asl, E. R., Hosseini, S. E., Tahmasebi, F., Bolandi, N., & Barati, S. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01578-6 · Cited by 19
Anal sphincter dysfunction in multiple sclerosis: an observation manometric study
Marola, S., Ferrarese, A., Gibin, E., Capobianco, M., Bertolotto, A., Enrico, S., Solej, M., Martino, V., Destefano, I., & Nano, M. (2016) · Open Medicine · doi:10.1515/med-2016-0088 · Cited by 18
EMDR treatment for anxiety in MS patients: A pilot study
Wallis, O. C., & de Vries, J. (2020) · Multiple Sclerosis Journal - Experimental, Translational and Clinical · doi:10.1177/2055217320974388 · Cited by 16
Giovannetti, A. M., Pakenham, K. I., Presti, G., Quartuccio, M. E., Confalonieri, P., Bergamaschi, R., Grobberio, M., Di Filippo, M., Micheli, M., Brichetto, G., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267245 · Cited by 11
Lin, T.-Y., Motamedi, S., Asseyer, S., Chien, C., Saidha, S., Calabresi, P. A., Fitzgerald, K. C., Samadzadeh, S., Villoslada, P., Llufriu, S., et al. (2024) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200269 · Cited by 12
Diffusivity in the core of chronic multiple sclerosis lesions
Klistorner, A., Wang, C., Yiannikas, C., Parratt, J., Barton, J., You, Y., Graham, S. L., & Barnett, M. H. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194142 · Cited by 11
Tong, L., Ozes, B., Moss, K., Myers, M., Attia, Z., Vetter, T. A., Trapp, B. D., & Sahenk, Z. (2025) · Gene Therapy · doi:10.1038/s41434-025-00518-9 · Cited by 8
Metadata
- Authors
- Lublin, F. D.
- Venue
- European Neurology
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 72
- Issue
- Suppl. 1
- Pages
- 1-5
- ISSN
- 0014-3022 (ISSN-L)
- 1421-9913
- OpenAlex
- W2142577589
- Cited by
- 4,259
- References
- 5
- FWCI
- 267.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.